NCT00394069已完成2 期
A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 3 to 6 Months
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
- 主要终点
- To evaluate the safety and tolerability of montelukast oral granules in children aged 3 to 6 months.
研究概览
简要总结
The purpose of this study is to look at the preliminary safety profile of an investigational drug in children 3 to 6 months of age with bronchiolitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 3 Months 至 6 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Montelukast sodium
Experimental
Participants receive montelukast sodium for 14 days.
干预措施: MK-0476, montelukast sodium (Drug)
结局指标
主要结局
To evaluate the safety and tolerability of montelukast oral granules in children aged 3 to 6 months.
时间窗: 14 days
次要结局
- To estimate the single-dose population pharmacokinetics, maximum plasma concentration, time to maximum plasma concentration, and apparent half-life of montelukast 4-mg oral granules in children aged 3 to 6 months.(24 hours)
研究者
相似试验
已完成
2 期
Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)BronchiolitisNCT00394160Organon and Co12
Unknown
3 期
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing RegimenPancreatic CancerNCT00088660Therion Biologics Corporation250
已完成
1 期
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease PatientsAlzheimer's DiseaseNCT01656525Chugai Pharmaceutical28
已完成
1 期
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult ParticipantsHealthy VolunteersNCT06088784HanAll BioPharma Co., Ltd.76
已完成
1 期
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaMultiple MyelomaNCT01063907Kyowa Kirin Co., Ltd.95